Oncotarget

Research Papers:

Marine compound rhizochalinin shows high in vitro and in vivo efficacy in castration resistant prostate cancer

Sergey A. Dyshlovoy _, Katharina Otte, Winfried H. Alsdorf, Jessica Hauschild, Tobias Lange, Simone Venz, Christiane K. Bauer, Robert Bähring, Kerstin Amann, Ramin Mandanchi, Udo Schumacher, Jennifer Schröder-Schwarz, Tatyana N. Makarieva, Alla G. Guzii, Kseniya M. Tabakmakher, Sergey N. Fedorov, Larisa K. Shubina, Igor E. Kasheverov, Heimo Ehmke, Thomas Steuber, Valentin A. Stonik, Carsten Bokemeyer, Friedemann Honecker and Gunhild von Amsberg

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:69703-69717. https://doi.org/10.18632/oncotarget.11941

Metrics: PDF 1358 views  |   HTML 1676 views  |   ?  


Abstract

Sergey A. Dyshlovoy1,2,3,*, Katharina Otte1,*, Winfried H. Alsdorf1, Jessica Hauschild1, Tobias Lange4, Simone Venz5, Christiane K. Bauer6, Robert Bähring6, Kerstin Amann7, Ramin Mandanchi1, Udo Schumacher4, Jennifer Schröder-Schwarz4, Tatyana N. Makarieva2, Alla G. Guzii2, Kseniya M. Tabakmakher2, Sergey N. Fedorov2, Larisa K. Shubina2, Igor E. Kasheverov8, Heimo Ehmke6, Thomas Steuber9, Valentin A. Stonik2, Carsten Bokemeyer1, Friedemann Honecker1,10, Gunhild von Amsberg1

1University Medical Center Hamburg-Eppendorf, Department of Oncology, Haematology and Bone Marrow Transplantation, Section Pneumology, Hubertus Wald -Tumorzentrum, Hamburg, Germany

2G.B. Elyakov Pacific Institute of Bioorganic Chemistry, Vladivostok, Russian Federation

3School of Natural Sciences, Far Eastern Federal University, Vladivostok, Russian Federation

4Department of Anatomy and Experimental Morphology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

5Department of Medical Biochemistry and Molecular Biology, University of Greifswald, Greifswald, Germany

6University Medical Center Hamburg-Eppendorf, Department of Cellular and Integrative Physiology, Hamburg, Germany

7Nephropathology Department, University Medical Center Erlangen, Erlangen, Germany

8Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia

9University Medical Center Hamburg-Eppendorf Martiniklinik, Prostate Cancer Center, Hamburg, Germany

10Tumor and Breast Center ZeTuP St. Gallen, St. Gallen, Switzerland

*These authors contributed equally to this work

Correspondence to:

Sergey A. Dyshlovoy, email: s.dyshlovoy@uke.de

Keywords: rhizochalinin, castration resistant prostate cancer, AR-V7, apoptosis, autophagy

Received: April 27, 2016     Accepted: September 02, 2016     Published: September 10, 2016

ABSTRACT

Development of drug resistance is an inevitable phenomenon in castration-resistant prostate cancer (CRPC) cells requiring novel therapeutic approaches. In this study, efficacy and toxicity of Rhizochalinin (Rhiz) – a novel sphingolipid-like marine compound – was evaluated in prostate cancer models, resistant to currently approved standard therapies. In vitro activity and mechanism of action of Rhiz were examined in the human prostate cancer cell lines PC-3, DU145, LNCaP, 22Rv1, and VCaP. Rhiz significantly reduced cell viability at low micromolar concentrations showing most pronounced effects in enzalutamide and abiraterone resistant AR-V7 positive cells. Caspase-dependent apoptosis, inhibition of pro-survival autophagy, downregulation of AR-V7, PSA and IGF-1 expression as well as inhibition of voltage-gated potassium channels were identified as mechanisms of action. Remarkably, Rhiz re-sensitized AR-V7 positive cells to enzalutamide and increased efficacy of taxanes.

In vivo activity and toxicity were evaluated in PC-3 and 22Rv1 NOD SCID mouse xenograft models using i.p. administration. Rhiz significantly reduced growth of PC-3 and 22Rv1 tumor xenografts by 27.0% (p = 0.0156) and 46.8% (p = 0.047) compared with controls with an increased fraction of tumor cells showing apoptosis secondary to Rhiz exposure. In line with the in vitro data, Rhiz was most active in AR-V7 positive xenografts in vivo. In animals, no severe side effects were observed.

In conclusion, Rhiz is a promising novel marine-derived compound characterized by a unique combination of anticancer properties. Its further clinical development is of high impact for patients suffering from drug resistant prostate cancer especially those harboring AR-V7 mediated resistance to enzalutamide and abiraterone.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11941